Article title: Prescription Medications for the Treatment of Obesity: NIDDK
Conditions: Obesity, Valvular heart disease, overweight, Primary pulmonary hypertension
Source: NIDDK
Most available weight-loss medications are "appetite-suppressant" medications. Appetite-suppressant medications promote weight loss by decreasing appetite or increasing the feeling of being full. These medications decrease appetite by increasing serotonin or catecholamine--two brain chemicals that affect mood and appetite.
In 1999, the drug orlistat was approved by the Food and Drug Administration (FDA) as an obesity treatment. Orlistat works by reducing the body's ability to absorb dietary fat by about one third.
Most currently available weight-loss medications are approved by the U.S. Food and Drug Administration (FDA) for short-term use, meaning a few weeks or months. Sibutramine and orlistat are the only weight-loss medications approved for longer-term use in significantly obese patients, although the safety and effectiveness have not been established for use beyond 1 year. (See table 1 for the generic and trade names of prescription weight-loss medications.) While the FDA regulates how a medication can be advertised or promoted by the manufacturer, these regulations do not restrict a doctor's ability to prescribe the medication for different conditions, in different doses, or for different lengths of time. The practice of prescribing medication for periods of time or for conditions not approved is known as "off-label" use. While such use often occurs in the treatment of many conditions, you should feel comfortable about asking your doctor if he or she is using a medication or combination of medications in a manner that is not approved by the FDA. The use of more than one weight-loss medication at a time (combined drug treatment) is an example of an off-label use. Using weight-loss medications other than sibutramine or orlistat for more than a short period of time (i.e., more than "a few weeks") is also considered off-label use.
Table 1
| Generic Name | Trade Name(s) |
|---|---|
| Dexfenfluramine | Redux (withdrawn) |
| Diethylpropion | Tenuate, Tenuate dospan |
| Fenfluramine | Pondimin (withdrawn) |
| Mazindol | Sanorex, Mazanor |
| Orlistat | Xenical |
| Phendimetrazine | Bontril, Plegine, Prelu-2, X-Trozine |
| Phentermine | Adipex-P, Fastin, Ionamin, Oby-trim |
| Sibutramine | Meridia |
Several weight-loss medications are available to treat obesity. In general, these medications are modestly effective, leading to an average weight loss of 5 to 22 pounds above that expected with non-drug obesity treatments. People respond differently to weight-loss medications, and some people experience more weight loss than others. Some obese patients using medication lose more than 10 percent of their starting body weight--an amount of weight loss that may reduce risk factors for obesity-related diseases, such as high blood pressure or diabetes. Maximum weight loss usually occurs within 6 months of starting medication treatment. Weight then tends to level off or increase during the remainder of treatment. Studies suggest that if a patient does not lose at least 4 pounds over 4 weeks on a particular medication, then that medication is unlikely to help the patient achieve significant weight loss. Few studies have looked at how safe or effective these medications are when taken for more than 1 year. Both orlistat and sibutramine have been studied for as long as 2 years in some patients.
Some antidepressant medications have been studied as appetite-suppressant medications. While these medications are FDA approved for the treatment of depression, their use in weight loss is an "off-label" use. Studies of these medications generally have found that patients lost modest amounts of weight for up to 6 months. However, most studies have found that patients who lost weight while taking antidepressant medications tended to regain weight while they were still on the drug treatment.
NOTE: Amphetamines and closely related compounds are not recommended for use in the treatment of obesity due to their potential for abuse and dependence.
Combined drug treatment using fenfluramine and phentermine ("fen/phen") is no longer available due to the withdrawal of fenfluramine from the market. Little information is available about the safety or effectiveness of other drug combinations for weight loss, including fluoxetine/phentermine, phendimetrazine/phentermine, Xenical/sibutramine, herbal combinations, or others. Until more information on their safety or effectiveness is available, using combinations of medications for weight loss is not recommended except as part of a research study.
Over the short term, weight loss in obese individuals may reduce a number of health risks. Studies looking at the effects of weight-loss medication treatment on obesity-related health risks have found that some agents lower blood pressure, blood cholesterol, and triglycerides (fats) and decrease insulin resistance (the body's inability to use blood sugar) over the short term. However, long-term studies are needed to determine if weight loss from weight-loss medications can improve health.
When considering long-term weight-loss medication treatment for obesity, you should consider the following areas of concern and potential risks.
Sibutramine acts on both the serotonin and catecholamine systems, but unlike fenfluramine and dexfenfluramine, sibutramine does not cause release of serotonin from cells. The primary known side effects of concern with sibutramine are elevations in blood pressure and pulse, which are usually small but may be significant in some patients. People with poorly controlled high blood pressure, heart disease, irregular heart beat, or history of stroke should not take sibutramine, and all patients taking the medication should have their blood pressure monitored on a regular basis.
Some side effects with orlistat include oily spotting, gas with discharge, urgent need to go to the bathroom, oily or fatty stools, an oily discharge, increased number of bowel movements, and inability to control bowel movements. These side effects are generally mild and temporary, but may be worsened by eating foods that are high in fat. Also, because orlistat reduces the absorption of some vitamins, patients should take a multivitamin at least 2 hours before or after taking orlistat.
Primary pulmonary hypertension (PPH) is a rare but potentially fatal disorder that affects the blood vessels in the lungs and results in death within 4 years in 45 percent of its victims. It should be noted that the vast majority of cases of PPH have occurred in patients who were taking fenfluramine or dexfenfluramine, either alone or in combination. There have been only a few case reports of PPH in patients taking phentermine alone, although the possibility that phentermine alone may be associated with PPH cannot be ruled out. No cases of PPH have been reported with sibutramine, but because of the low incidence of this disease in the underlying population, it is not known whether or not sibutramine may cause this disease.
Q: Can medications replace physical activity or changes in eating habits as a way to lose weight?
A: No. The use of weight-loss medications to treat obesity should be combined with physical activity and improved diet to lose and maintain weight successfully over the long term.
Q: Will I regain some weight after I stop taking weight-loss
medications?
A: Probably. Most studies show that the majority of patients who stop taking weight-loss medications regain the weight they had lost. Maintaining healthy eating and physical activity habits will increase your likelihood of keeping weight off.
Q: How long will I need to take weight-loss medications to treat
obesity?
A: The answer depends upon whether the medication helps you to lose and maintain weight and whether you have any side effects. Because obesity is a chronic disease, any treatment, whether drug or nondrug, may need to be continued for years, and perhaps a lifetime, to improve health and maintain a healthy weight. There is little information on how safe and effective weight-loss medications are for many years of use.
Q: What dosage of weight-loss medication would be right for
me?
A: There is no one correct dose for weight loss medications. Your doctor will decide what works best for you based on his or her evaluation of your medical condition and response to treatment.
Q: I only need to lose 10 pounds. Are weight-loss medications
appropriate for me?
A: Weight-loss medications may be appropriate for carefully selected patients who are at significant medical risk because of their obesity. They are not recommended for use by people who are only mildly overweight unless they have health problems that are made worse by their weight. These medications should not be used only to improve appearance.
Before choosing weight-loss medication for the long-term management of obesity, you should talk to your doctor about any concerns you may have. In addition, it is important that you discuss the following issues with your doctor.
How will I be evaluated to determine if I am an appropriate
candidate for weight-loss medication?
Your physician will look at a number of factors to determine if you are a good candidate for prescription weight-loss medication. He or she will determine how overweight you are and where your body fat is distributed (see WIN's fact sheet Understanding Adult Obesity for further information). Your doctor may do the following:
What other medical conditions or medications might influence
my decision to take a weight-loss medication?
It is important that you notify your physician if you have any of the following medical conditions:
Studies show that weight-loss medications work best when combined with a weight-management program that helps you improve your eating and physical activity habits. Ask your doctor any questions or concerns that you may have about good nutrition and physical activity.
If you and your doctor believe that the use of weight-loss medications may help you, discussing the goals of treatment is important. Improving your health and reducing your risk for disease should be the primary goals. For most severely obese people, achieving an "ideal body weight" is both unrealistic and unnecessary to improve their health and reduce their risk for disease. Most patients should not expect to reach an ideal body weight using the currently available medications. Even a modest weight loss of 5 to 10 percent of your starting body weight can improve your health and reduce your risk factors for disease. Use of weight-loss medications for cosmetic purposes is not appropriate.
Weight-loss medications should be used with a program of behavioral treatment and nutritional counseling designed to help you make long-term changes in your diet and physical activity. You should see your physician regularly so that he or she can monitor how you are responding to the medication, not only in terms of weight loss, but how it affects your overall health. Again, if you experience any serious symptoms, such as chest pains or shortness of breath, contact your doctor immediately.
Long-term use of prescription weight-loss medications may be helpful for carefully selected individuals, but little information is available on the safety and effectiveness of these medications when used for more than 2 years. By evaluating your risk of experiencing obesity-related health problems, you and your physician can make an informed choice as to whether medication can be a useful part of your weight-management program.
End note: This e-text is a modified version of a review
article on the long-term use of appetite-suppressant medications to manage
obesity appearing in a 1996 issue of the Journal of the American
Medical Association. Both the review article and this fact sheet were
developed with the advice of the National Task Force on Prevention and
Treatment of Obesity, a working group of leading obesity and nutrition
researchers from across the country. This e-text was revised in October
1997 in response to additional information reported regarding an
association between valvular heart disease and certain weight-loss
medications, in February 1998 in response to the approval of sibutramine,
and in November 2000 in response to the approval of orlistat.
1 Win Way
Bethesda, MD 20892-3665
Phone: (202) 828-1025 or 1-877-946-4627
Fax: (202) 828-1028
Email: win@info.niddk.nih.gov
The Weight-control Information Network (WIN) is a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, under the U.S. Public Health Service. Authorized by Congress (Public Law 103-43), WIN assembles and disseminates to health professionals and the public information on weight control, obesity, and nutritional disorders. WIN responds to requests for information; develops, reviews, and distributes publications; and develops communications strategies to encourage individuals to achieve and maintain a healthy weight.
Publications produced by the clearinghouse are carefully reviewed by both NIDDK scientists and outside experts.
This e-text is not copyrighted. The network encourages users of this e-pub to duplicate and distribute as many copies as desired.
NIH Publication No. 97-4191
December 1996
Updated: February 2001
» Next page: Preventing Cryptosporidiosis: A Guide for People with Compromised Immune Systems: DPD
What do you think about the features of this website? Take our user survey and have your say:
Tools & Services:
Medical Articles:
Search Specialists by State and City
By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.
Copyright © 2009 Health Grades Inc. All rights reserved.
